SAN DIEGO, March 29, 2022 /PRNewswire/ -- Angiocrine Bioscience, Inc., a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 3 registration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results